Polycyclic Agents for the Treatment of Respiratory Syncytial Virus Infections

Abstract

Compounds of formula (I), and their use as in the treatment of infections involving viruses of the Pneumovirinae sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, pyridyl etc., (B-C) may be CH2—CH2 etc., (R1) may be phenyl and substituted forms thereof, (R2) may be assorted substituents.

Description

FIELD OF THE INVENTION[0001]The present invention relates to antiviral compounds, methods for their preparation and compositions containing them, and use at the compounds and composition in the treatment of viral infections. In particular, the invention relates to the use of compounds of formula I for the treatment of respiratory syncytial virus infection.BACKGROUND ART[0002]Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in adults and in young children. In the western world approximately all children have been infected by the age of two. In most cases the RSV infections will only cause minor upper respiratory illness with symptoms resembling that of the common cold. However, severe infection with the virus may result in bronchiolitis or pneumonia which may result in hospitalization or death. Infants who have been born prematurely or have a pre-existing lung disease are a high risk of severe infection and complications.[0003]Respiratory sy...

AI Technical Summary

Benefits of technology

The compounds effectively inhibit RSV fusion processes, offering a safer and more effective treatment option compared to existing antiviral medications, with potential for reduced toxicity and improved patient outcomes.

Problems solved by technology

However, severe infection with the virus may result in bronchiolitis or pneumonia which may result in hospitalization or death.

Infants who have been born prematurely or have a pre-existing lung disease are a high risk of severe infection and complications.

Unfortunately, the agent is toxic so that administration of the agent is confined to a hospital setting.

Its administration is further complicated by the need to follow a strict procedural process when administering the agent in order to minimise the likelihood of certain adverse affects.

The agent has a number of adverse effects including sudden deterioration of respiratory function (bronchiospasm).

Images